المؤلفون: Caly, H., Rabiei, H., Coste-Mazeau, P., Hantz, S., Alain, S., Eyraud, J. L., Chianea, T., Caly, C., Makowski, D., Hadjikhani, Nouchine, 1966, Lemonnier, E., Ben-Ari, Y.

المصدر: Scientific Reports. 11

مصطلحات موضوعية: Psychiatry, Psykiatri, Science & Technology - Other Topics

URL الوصول: https://gup.ub.gu.se/publication/304390

المؤلفون: Yehezkel Ben-Ari, Nouchine Hadjikhani, Eric Lemonnier, Hamed Rabiei, Sophie Alain, Thierry Chianea, David Makowski, H. Caly, Jean-Luc Eyraud, Coste-Mazeau P, Caly C, Sébastien Hantz

مصطلحات موضوعية: education.field_of_study, Pregnancy, Pediatrics, medicine.medical_specialty, Fetus, business.industry, Population, medicine.disease, Autism spectrum disorder, medicine, Gestation, Autism, False positive rate, education, business, Neurotypical

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::715ffabd0fa37a8b59ef7e9063b9f0da
https://doi.org/10.1101/2020.07.08.192989

المؤلفون: Wang-Gillam A; Washington University School of Medicine, St. Louis, MO, USA. wanggillamay@hotmail.com., Schelman W; HUTCHMED International Corporation, Florham Park, NJ, USA., Ukrainskyj S; HUTCHMED International Corporation, Florham Park, NJ, USA., Chien C; HUTCHMED International Corporation, Florham Park, NJ, USA., Gonzalez M; HUTCHMED International Corporation, Florham Park, NJ, USA., Yang Z; HUTCHMED International Corporation, Florham Park, NJ, USA., Kania M; HUTCHMED International Corporation, Florham Park, NJ, USA., Yeckes-Rodin H; Hematology Oncology Associates of the Treasure Coast, Port St. Lucie, FL, USA.

المصدر: Investigational new drugs [Invest New Drugs] 2023 Dec; Vol. 41 (6), pp. 851-860. Date of Electronic Publication: 2023 Oct 05.

نوع المنشور: Clinical Trial, Phase I; Journal Article

بيانات الدورية: Publisher: Springer Country of Publication: United States NLM ID: 8309330 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-0646 (Electronic) Linking ISSN: 01676997 NLM ISO Abbreviation: Invest New Drugs Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents*/adverse effects , Neoplasms*/drug therapy , Neoplasms*/pathology , Benzofurans*/adverse effects, Humans ; Quinazolines/adverse effects ; Maximum Tolerated Dose

المؤلفون: Arifuddin A; Doctoral Program in Education Research and Evaluation, Universitas Negeri Yogyakarta, Indonesia.; Faculty of Public Health, Universitas Tadulako, Indonesia.; Master Program in Education Research and Evaluation, Universitas Sarjanawiyata Tamansiswa, Indonesia., Zuchdi D; Doctoral Program in Education Research and Evaluation, Universitas Negeri Yogyakarta, Indonesia., Rosana D; Doctoral Program in Education Research and Evaluation, Universitas Negeri Yogyakarta, Indonesia., Arovah NI; Doctoral Program in Education Research and Evaluation, Universitas Negeri Yogyakarta, Indonesia., Setiawan C; Doctoral Program in Education Research and Evaluation, Universitas Negeri Yogyakarta, Indonesia., Prihatni Y; Master Program in Education Research and Evaluation, Universitas Sarjanawiyata Tamansiswa, Indonesia., Setiawan A; Master Program in Education Research and Evaluation, Universitas Sarjanawiyata Tamansiswa, Indonesia., Nur AF; Department of Midwifery, Universitas Widya Nusantara, Indonesia., Dyastuti NE; Department of Midwifery, Universitas Widya Nusantara, Indonesia., Arifuddin H; Department of Midwifery, Poltekkes Jakarta 1, Indonesia.

المصدر: Journal of education and health promotion [J Educ Health Promot] 2023 Sep 29; Vol. 12, pp. 307. Date of Electronic Publication: 2023 Sep 29 (Print Publication: 2023).

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Medknow Publications & Media Pvt. Ltd Country of Publication: India NLM ID: 101593794 Publication Model: eCollection Cited Medium: Print ISSN: 2277-9531 (Print) Linking ISSN: 22779531 NLM ISO Abbreviation: J Educ Health Promot Subsets: PubMed not MEDLINE

المؤلفون: Dasari A; MD Anderson Cancer Center, Houston, TX, USA. ADasari@mdanderson.org., Hamilton EP; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA., Falchook GS; Sarah Cannon Research Institute at HealthONE, Denver, CO, USA., Wang JS; Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, USA., Li D; City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, CA, USA., Sung MW; Tisch Institute at The Icahn School of Medicine at Mount Sinai, New York, NY, USA., Chien C; HUTCHMED International Corporation, Florham Park, NJ, USA., Nanda S; HUTCHMED International Corporation, Florham Park, NJ, USA., Tucci C; HUTCHMED International Corporation, Florham Park, NJ, USA., Hahka-Kemppinen M; HUTCHMED International Corporation, Florham Park, NJ, USA., Paulson AS; Baylor Sammons Cancer Center, Dallas, TX, USA.

المصدر: Investigational new drugs [Invest New Drugs] 2023 Jun; Vol. 41 (3), pp. 421-430. Date of Electronic Publication: 2023 Apr 19.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Springer Country of Publication: United States NLM ID: 8309330 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-0646 (Electronic) Linking ISSN: 01676997 NLM ISO Abbreviation: Invest New Drugs Subsets: MEDLINE

مواضيع طبية MeSH: Neuroendocrine Tumors*/drug therapy , Neuroendocrine Tumors*/pathology , Neoplasms*/pathology , Neuroectodermal Tumors, Primitive*/chemically induced, Humans ; Vascular Endothelial Growth Factor Receptor-1 ; Tyrosine Kinase Inhibitors ; Vascular Endothelial Growth Factor A ; Protein Kinase Inhibitors/adverse effects ; Maximum Tolerated Dose

المؤلفون: T'jollyn H; Clinical Pharmacology and Pharmacometrics, Janssen Research and Development, Turnhoutseweg 30, 2340, Beerse, Belgium., Ackaert O; Clinical Pharmacology and Pharmacometrics, Janssen Research and Development, Turnhoutseweg 30, 2340, Beerse, Belgium. oackaert@its.jnj.com., Chien C; Clinical Pharmacology, Hutchison MediPharma International, Florham Park, NJ, USA., Lopez-Gitlitz A; Janssen Research & Development, Los Angeles, USA., McCarthy S; Janssen Research and Development, Raritan, NJ, USA., Ruixo CP; Clinical Pharmacology and Pharmacometrics, Janssen Research and Development, Turnhoutseweg 30, 2340, Beerse, Belgium., Karsh L; The Urology Center of Colorado, Denver, CO, USA., Chi K; BC Cancer and Vancouver Prostate Centre, Vancouver, Canada., Chowdhury S; Guy's, King's, and St. Thomas' Hospitals and the Sarah Cannon Research Institute, London, UK., Ruixo JP; Clinical Pharmacology and Pharmacometrics, Janssen Research and Development, Turnhoutseweg 30, 2340, Beerse, Belgium., Agarwal N; Huntsman Cancer Institute, University of Utah, Salt Lake City, USA.

المصدر: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2022 May; Vol. 89 (5), pp. 629-641. Date of Electronic Publication: 2022 Apr 02.

نوع المنشور: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0843 (Electronic) Linking ISSN: 03445704 NLM ISO Abbreviation: Cancer Chemother Pharmacol Subsets: MEDLINE

مواضيع طبية MeSH: Exanthema*/chemically induced , Prostatic Neoplasms, Castration-Resistant*, Androgen Antagonists/adverse effects ; Castration ; Humans ; Male ; Pruritus/chemically induced ; Thiohydantoins

المؤلفون: Dasari A; Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 426, Houston, TX 77030, USA., Sobrero A; Ospedale Policlinico San Martino - IRCCS, Largo R. Benzi n.10, Ospedale Policlinico San Martino, Padiglione ex Microbiologia, Piano Terra Levante, 16132, Genova, Italy., Yao J; Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 426, Houston, TX 77030, USA., Yoshino T; Department of Gastroenterology & Gastrointestinal Oncology, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 270-8577, Japan., Schelman W; Clinical Development, Hutchison MediPharma International Incorporated, 25A Vreeland Road, Suite 304, Florham Park, NJ 07932, USA., Yang Z; Biostatistics, Hutchison MediPharma International Incorporated, 25A Vreeland Road, Suite 304, Florham Park, NJ 07932, USA., Chien C; Clinical Pharmacology, Hutchison MediPharma International Incorporated, 25A Vreeland Road, Suite 304, Florham Park, NJ 07932, USA., Kania M; Clinical Development, Hutchison MediPharma International Incorporated, 25A Vreeland Road, Suite 304, Florham Park, NJ 07932, USA., Tabernero J; Department of Medical Oncology, Vall d'Hebron Hospital Campus & Vall d'Hebron Institute of Oncology (VHIO), IOB-Quiron, UVic-UCC, Passeig Vall d'Hebron 119-129, Barcelona, 08035, Spain., Eng C; Division of Hematology & Oncology, Vanderbilt-Ingram Cancer Center, 2220 Pierce Ave, 777 PRB, Nashville, TN 37232, USA.

المصدر: Future oncology (London, England) [Future Oncol] 2021 Aug; Vol. 17 (24), pp. 3151-3162. Date of Electronic Publication: 2021 May 17.

نوع المنشور: Clinical Trial Protocol; Journal Article

بيانات الدورية: Publisher: Future Medicine Ltd Country of Publication: England NLM ID: 101256629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8301 (Electronic) Linking ISSN: 14796694 NLM ISO Abbreviation: Future Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Angiogenesis Inhibitors*/therapeutic use , Antineoplastic Agents*/therapeutic use , Benzofurans*/therapeutic use , Colorectal Neoplasms*/drug therapy , Protein Kinase Inhibitors*/therapeutic use , Quinazolines*/therapeutic use, Humans ; Double-Blind Method ; Clinical Trials, Phase III as Topic ; Randomized Controlled Trials as Topic ; Multicenter Studies as Topic

المؤلفون: Perez-Ruixo C; Janssen Research & Development, Antwerp, Belgium., Ackaert O; Janssen Research & Development, Antwerp, Belgium. oackaert@its.jnj.com., Ouellet D; Janssen Research & Development, Spring House, Pennsylvania., Chien C; Janssen Research & Development, Spring House, Pennsylvania., Uemura H; Yokohama City University Medical Center, Yokohama, Japan., Olmos D; Spanish National Cancer Research Centre (CNIO), Madrid, and Hospitales Universitarios Virgen de la Victoria y Regional, Institute of Biomedical Research in Málaga (IBIMA), Spain., Mainwaring P; Centre for Personalised Nanomedicine, University of Queensland, Brisbane, Australia., Lee JY; Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea., Yu MK; Janssen Research & Development, Los Angeles, California., Perez-Ruixo JJ; Janssen Research & Development, Antwerp, Belgium., Smith MR; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts., Small EJ; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2020 Sep 01; Vol. 26 (17), pp. 4460-4467. Date of Electronic Publication: 2020 Jun 19.

نوع المنشور: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Androgen Receptor Antagonists/*administration & dosage , Drug Eruptions/*epidemiology , Prostatic Neoplasms, Castration-Resistant/*drug therapy , Thiohydantoins/*administration & dosage , Weight Loss/*drug effects, Adult ; Androgen Receptor Antagonists/adverse effects ; Androgen Receptor Antagonists/pharmacokinetics ; Area Under Curve ; Dose-Response Relationship, Drug ; Drug Eruptions/etiology ; Humans ; Male ; Middle Aged ; Progression-Free Survival ; Prostatic Neoplasms, Castration-Resistant/mortality ; Prostatic Neoplasms, Castration-Resistant/pathology ; Thiohydantoins/adverse effects ; Thiohydantoins/pharmacokinetics

المؤلفون: Duran I; Hospital Universitario Virgen del Rocío, Seville, Spain., Carles J; Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain., Bulat I; ARENSIA Exploratory Medicine, Institute of Oncology Unit, Chisinau, Moldova., Hellemans P; Janssen Research & Development, Beerse, Belgium. phellema@its.jnj.com., Mitselos A; Janssen Research & Development, Beerse, Belgium., Ward P; Janssen Research & Development, San Diego, CA, USA., Jiao J; Janssen Research & Development, Raritan, NJ, USA., Armas D; Celerion, Tempe, AZ, USA., Chien C; Janssen Research & Development, Spring House, PA, USA.

المصدر: Clinical pharmacokinetics [Clin Pharmacokinet] 2020 Sep; Vol. 59 (9), pp. 1135-1148.

نوع المنشور: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Country of Publication: Switzerland NLM ID: 7606849 Publication Model: Print Cited Medium: Internet ISSN: 1179-1926 (Electronic) Linking ISSN: 03125963 NLM ISO Abbreviation: Clin Pharmacokinet Subsets: MEDLINE

مواضيع طبية MeSH: Prostatic Neoplasms, Castration-Resistant*/drug therapy, Cytochrome P-450 Enzyme Inhibitors/*pharmacokinetics , Thiohydantoins/*pharmacokinetics, Drug Interactions ; Humans ; Male ; Neoplasm Proteins

المؤلفون: Van den Bergh A; Janssen Research & Development, Turnhoutseweg 30, 2340, Beerse, Belgium. avdberg2@its.jnj.com., Snoeys J; Janssen Research & Development, Turnhoutseweg 30, 2340, Beerse, Belgium., De Zwart L; Janssen Research & Development, Turnhoutseweg 30, 2340, Beerse, Belgium., Ward P; Janssen Research & Development, San Diego, CA, USA., Lopez-Gitlitz A; Janssen Research & Development, Los Angeles, CA, USA., Ouellet D; Janssen Research & Development, Spring House, PA, USA., Monshouwer M; Janssen Research & Development, Turnhoutseweg 30, 2340, Beerse, Belgium., Chien C; Janssen Research & Development, Spring House, PA, USA.

المصدر: Clinical pharmacokinetics [Clin Pharmacokinet] 2020 Sep; Vol. 59 (9), pp. 1149-1160.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Country of Publication: Switzerland NLM ID: 7606849 Publication Model: Print Cited Medium: Internet ISSN: 1179-1926 (Electronic) Linking ISSN: 03125963 NLM ISO Abbreviation: Clin Pharmacokinet Subsets: MEDLINE

مواضيع طبية MeSH: Cytochrome P-450 CYP2C8 Inducers* , Cytochrome P-450 CYP3A Inhibitors*, Androgen Receptor Antagonists/*pharmacokinetics , Thiohydantoins/*pharmacokinetics, Area Under Curve ; Cytochrome P-450 CYP3A/metabolism ; Drug Interactions ; Humans